Skip to main content

Advertisement

SpringerLink
Log in

GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

This database analysis of over 4,000 German women prescribed oral bisphosphonates between December 2004 and November 2007 showed that compliance and persistence with oral bisphosphonates in German women with osteoporosis were inadequate.

Introduction

GRAND is a database analysis designed to investigate persistence and compliance with oral bisphosphonate regimens, and their association with fracture incidence, in women with osteoporosis.

Methods

Diagnostic, treatment and fracture data were obtained from the IMS® Disease Analyzer patient database in Germany. Women with osteoporosis prescribed one of six specified oral bisphosphonates between December 2004 and November 2007 with no similar prescription for at least 1 year beforehand were eligible for analysis. Those treated with intravenous bisphosphonates were excluded. Persistence (prescription refill gap of ≤30 days or change of treatment frequency) and compliance (medication possession ratio) were measured for 2 years from therapy start.

Results

Data from 4,147 women were evaluable, with a median oral bisphosphonate treatment duration of 145.5 days. Persistence rates after 1 and 2 years were 27.9% and 12.9%, respectively, and 66.3% of women were compliant. As expected, persistence rates were higher when the refill gap was increased to 60 or 90 days. No significant differences in 1-year persistence between patients on weekly or monthly treatment regimens were observed (28.6% and 29.4%, respectively), although 1-year persistence with daily treatment was only 7.2%. After 24 months of therapy, compliant women had fewer fractures than non-compliant women (88.1% and 85.0% fracture-free, respectively; p = 0.0147). In multivariate Cox regression analysis, treatment compliance was the only factor that significantly decreased fracture risk (p = 0.0034).

Conclusions

Compliance and persistence with oral bisphosphonates in German women with osteoporosis were inadequate. Better compliance and persistence can prevent fractures in these women.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Kanis JA, Reginster JY (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women—what is the current message for clinical practice? Pol Arch Med Wewn 118:538–540

    PubMed  Google Scholar 

  2. Cooper C (1999) Epidemiology of osteoporosis. Osteoporos Int 9(Suppl 2):S2–S8

    Article  PubMed  Google Scholar 

  3. Reginster JY, Burlet N (2006) Osteoporosis: a still increasing prevalence. Bone 38(Suppl 1):4–9

    Article  Google Scholar 

  4. Cole ZA, Dennison EM, Cooper C (2008) Osteoporosis epidemiology update. Curr Rheumatol Rep 10:92–96

    Article  PubMed  Google Scholar 

  5. Glüer CC, Eastell R, Reid DM, Felsenberg D, Roux C, Barkmann R, Timm W, Blenk T, Armbrecht G, Stewart A, Clowes J, Thomasius FE, Kolta S (2004) Association of five quantitative ultrasound devices and bone densitometry with osteoporotic vertebral fractures in a population-based sample: the OPUS Study. J Bone Miner Res 19:782–793

    Article  PubMed  Google Scholar 

  6. Haussler B, Gothe H, Gol D, Glaeske G, Pientka L, Felsenberg D (2007) Epidemiology, treatment and costs of osteoporosis in Germany—the BoneEVA Study. Osteoporos Int 18:77–84

    Article  PubMed  CAS  Google Scholar 

  7. Ismail AA, Pye SR, Cockerill WC, Lunt M, Silman AJ, Reeve J, Banzer D, Benevolenskaya LI, Bhalla A, Bruges AJ, Cannata JB, Cooper C, Delmas PD, Dequeker J, Dilsen G, Falch JA, Felsch B, Felsenberg D, Finn JD, Gennari C, Hoszowski K, Jajic I, Janott J, Johnell O, Kanis JA, Kragl G, Lopez VA, Lorenc R, Lyritis G, Marchand F, Masaryk P, Matthis C, Miazgowski T, Naves-Diaz M, Pols HA, Poor G, Rapado A, Raspe HH, Reid DM, Reisinger W, Scheidt-Nave C, Stepan J, Todd C, Weber K, Woolf AD, O’Neill TW (2002) Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int 13:565–571

    Article  PubMed  CAS  Google Scholar 

  8. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12:989–995

    Article  PubMed  CAS  Google Scholar 

  9. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R, European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428

    Article  PubMed  CAS  Google Scholar 

  10. Dachverbands der Deutschsprachigen Wissenschaftlichen Osteologischen Gesellschaften e.V (2009) DVO-Leitlinie 2009 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Erwachsenen. Osteologie 4:304–324

    Google Scholar 

  11. Brankin E, Walker M, Lynch N, Aspray T, Lis Y, Cowell W (2006) The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Curr Med Res Opin 22:1249–1256

    Article  PubMed  CAS  Google Scholar 

  12. Cotte FE, Mercier F, De PG (2008) Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case–control analysis. Clin Ther 30:2410–2422

    Article  PubMed  Google Scholar 

  13. Curtis JR, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E (2008) Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 23:1435–1441

    Article  PubMed  Google Scholar 

  14. Penning-van Beest FJA, Erkens JA, Olson M, Herings RM (2008) Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 19:511–517

    Article  PubMed  CAS  Google Scholar 

  15. Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811–818

    Article  PubMed  CAS  Google Scholar 

  16. Weycker D, Macarios D, Edelsberg J, Oster G (2007) Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int 18:271–277

    Article  PubMed  CAS  Google Scholar 

  17. Adachi J, Lynch N, Middelhoven H, Hunjan M, Cowell W (2007) The association between compliance and persistence with bisphosphonate therapy and fracture risk: a review. BMC Musculoskelet Disord 8:97

    Article  PubMed  Google Scholar 

  18. Cramer JA, Lynch NO, Gaudin AF, Walker M, Cowell W (2006) The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther 28:1686–1694

    Article  PubMed  CAS  Google Scholar 

  19. Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023–1031

    Article  PubMed  CAS  Google Scholar 

  20. Kertes J, Dushenat M, Vesterman JL, Lemberger J, Bregman J, Friedman N (2008) Factors contributing to compliance with osteoporosis medication. Isr Med Assoc J 10:207–213

    PubMed  Google Scholar 

  21. Recker RR, Gallagher R, MacCosbe PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80:856–861

    Article  PubMed  Google Scholar 

  22. Bartl R, Gotte S, Hadji P, Hammerschmidt T (2006) Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment. Dtsch Med Wochenschr 131:1257–1262

    Article  PubMed  CAS  Google Scholar 

  23. Höer A, Seidlitz C, Gothe H, Schiffhorst G, Olson M, Hadji P, Häussler B (2009) Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. Patient Prefer Adherence 3:25–30

    PubMed  Google Scholar 

  24. Becher H, Kostev K, Schroder-Bernhardi D (2009) Validity and representativeness of the “Disease Analyzer” patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther 47:617–626

    PubMed  CAS  Google Scholar 

  25. DIMDI (2007) ICD-10-GM version 2008. Deutsches Institut für Medizinische Dokumentation und Information, Cologne

  26. DGEpi (2010) Leitlinien Und Empfehlungen Zur Sicherung Von Guter Epidemiologischer Praxis. Deutsche Gesellschaft für Epidemiologie, Hannover

    Google Scholar 

  27. Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122:S3–S13

    Article  PubMed  Google Scholar 

  28. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB (2009) Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 15:728–740

    PubMed  Google Scholar 

  29. Rabenda V, Hiligsmann M, Reginster JY (2009) Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother 10:2303–2315

    Article  PubMed  CAS  Google Scholar 

  30. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022

    Article  PubMed  Google Scholar 

  31. Briesacher BA, Andrade SE, Fouayzi H, Chan KA (2008) Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 28:437–443

    Article  PubMed  Google Scholar 

  32. Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928

    Article  PubMed  Google Scholar 

  33. Col N, Fanale JE, Kronholm P (1990) The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med 150:841–845

    Article  PubMed  CAS  Google Scholar 

  34. Cranney A, Jamal SA, Tsang JF, Josse RG, Leslie WD (2007) Low bone mineral density and fracture burden in postmenopausal women. CMAJ 177:575–580

    Article  PubMed  Google Scholar 

  35. Blouin J, Dragomir A, Fredette M, Ste-Marie LG, Fernandes JC, Perreault S (2009) Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. Osteoporos Int 20:1571–1581

    Article  PubMed  CAS  Google Scholar 

  36. Guilera M, Fuentes M, Grifols M, Ferrer J, Badia X (2006) Does an educational leaflet improve self-reported adherence to therapy in osteoporosis? The OPTIMA Study. Osteoporos Int 17:664–671

    Article  PubMed  CAS  Google Scholar 

  37. Reginster JY (2006) Adherence and persistence: impact on outcomes and health care resources. Bone 38(Suppl 2):S18–S21

    Article  PubMed  Google Scholar 

  38. Schousboe JT, Dowd BE, Davison ML, Kane RL (2010) Association of medication attitudes with non-persistence and non-compliance with medication to prevent fractures. Osteoporos Int 21:1899–1909

    Article  PubMed  CAS  Google Scholar 

  39. Haynes RB, McKibbon KA, Kanani R (1996) Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet 348:383–386

    Article  PubMed  CAS  Google Scholar 

  40. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X (2008) Interventions for enhancing medication adherence. Cochrane Database Syst Rev:CD000011

  41. Castelo-Branco C, Cortés X, Ferrer M (2010) Treatment persistence and compliance with a combination of calcium and vitamin D. Climacteric 13:578–584

    Article  PubMed  CAS  Google Scholar 

  42. Huas D, Debiais F, Blotman F, Cortet B, Mercier F, Rousseaux C, Berger V, Gaudin AF, Cotté FE (2010) Compliance and treatment satisfaction of post menopausal women treated for osteoporosis. Compliance with osteoporosis treatment. BMC Womens Health 10:26

    Article  PubMed  Google Scholar 

  43. Cotté FE, Fardellone P, Mercier F, Gaudin AF, Roux C (2009) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21:145–155

    Article  PubMed  Google Scholar 

  44. Silverman SL, Schousboe JT, Gold DT (2011) Oral bisphosphonate compliance and persistence: a matter of choice? Osteoporos Int 22:21–26

    Article  PubMed  CAS  Google Scholar 

  45. Ojeda-Bruno S, Naranjo A, Francisco-Hernández F, Erausquin C, Rúa-Figueroa I, Quevedo JC, Rodríguez-Lozano C (2011) Secondary prevention program for osteoporotic fractures and long-term adherence to bisphosphonates. Osteoporos Int. doi:10.1007/s00198-010-1414-z

Download references

Acknowledgements

This study was sponsored by Amgen (Europe) GmbH. Amgen (Europe) GmbH and GlaxoSmithKline Ltd. provided funds to Bioscript Stirling Ltd. for editing/formatting assistance and to Surfmedia for graphics support.

Conflicts of interest

Dr. Hadji has received honoraria, unrestricted educational grants and research funding from the following companies: Amgen, AstraZeneca, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, Procter & Gamble and Roche. Dr. Ziller has no conflict of interest. V Claus and K Kostev are employees of IMS Health GmbH & Co. OHG. T Steinle is an employee of Amgen, Germany. M Intorcia is an employee of Amgen (Europe), Switzerland.

Author information

Authors and Affiliations

  1. Klinik für Gynäkologie, Gynäkologische Endokrinologie und Onkologie, Philipps-University, Marburg, Germany

    P. Hadji & V. Ziller

  2. Health Economics & Outcomes Research, IMS Health GmbH & Co. OHG, Munich, Germany

    V. Claus

  3. iHE, Amgen (Europe) GmbH, Zug, Switzerland

    M. Intorcia

  4. Centre of Excellence Patient Data, IMS Health GmbH & Co. OHG, Munich, Germany

    K. Kostev

  5. Health Economics, Amgen GmbH, Munich, Germany

    T. Steinle

Authors
  1. P. Hadji
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Claus
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. Ziller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Intorcia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. Kostev
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. Steinle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V. Claus.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hadji, P., Claus, V., Ziller, V. et al. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 23, 223–231 (2012). https://doi.org/10.1007/s00198-011-1535-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-011-1535-z

Keywords

Search

Navigation